Resident, Oral and Maxillofacial Surgery, Kings County Hospital Center, Brooklyn, NY.
Professor and Vice-Chairman, Oral Maxillofacial Surgery Program Director, Retired, Kings County Hospital Center/SUNY Brooklyn, Brooklyn, NY.
J Oral Maxillofac Surg. 2022 Jan;80(1):101-112. doi: 10.1016/j.joms.2021.08.155. Epub 2021 Sep 17.
Secretory carcinoma (SC) of the salivary gland, formerly known as mammary analogue secretory carcinoma, is an uncommon and fairly newly described low grade malignant neoplasm of the salivary gland. Given the small number of cases reported in the literature to date, treatment guidelines are scarce. This study aimed to describe the clinical characteristics of SC, discuss prior management strategies, and provide recommendations for future treatment.
We performed a systematic review of all the cases of SC reported in the literature since it was first recognized in 2010. Using Pubmed, Crossref, and Google Scholar, we identified all articles reporting cases of SC.
We identified 657 cases of SC in 109 articles. In addition, we provided 2 new cases, for a total of 659 cases in 110 articles. To our knowledge, this is the largest review of cases of SC in the literature to date. We summarized the clinical characteristics of SC, as well as the nodal status, clinical management, recurrence rate, and death rate.
SC occurs on average in middle age (with a large age range), presents most often initially as localized disease without metastasis, and has a low but not insignificant recurrence rate. Deaths have been reported. The generalized recommendations for treatment of SC are in line with those of other low-grade salivary gland malignancies.
涎腺分泌性癌(SC),以前称为乳腺样分泌性癌,是一种罕见且最近才被描述的低级别涎腺恶性肿瘤。鉴于迄今为止文献中报道的病例数量较少,治疗指南稀缺。本研究旨在描述 SC 的临床特征,讨论先前的管理策略,并为未来的治疗提供建议。
我们对自 2010 年首次被确认以来文献中报道的所有 SC 病例进行了系统回顾。使用 Pubmed、Crossref 和 Google Scholar,我们确定了所有报道 SC 病例的文章。
我们在 109 篇文章中发现了 657 例 SC,另外还提供了 2 例新病例,总计 110 篇文章中的 659 例。据我们所知,这是迄今为止文献中对 SC 病例的最大回顾。我们总结了 SC 的临床特征,以及淋巴结状态、临床管理、复发率和死亡率。
SC 平均发生在中年(年龄范围较大),最初通常表现为局部疾病且无转移,复发率虽低但并非微不足道。已报道有死亡病例。SC 的一般治疗建议与其他低级别涎腺恶性肿瘤的治疗建议一致。